Showing posts with label Reports. Show all posts
Showing posts with label Reports. Show all posts

Wednesday, February 29, 2012

Neuritis, acute and chronic, in leprosy


Leprosy Mailing List – February 28th, 2012 
Ref.:    Neuritis, acute and chronic, in leprosy
From:  H Srinivasan, Chennai, India

Dear Dr Noto,
The following are my views regarding the queries raised about "Acute neuritis" in leprosy.  I think it will help starting from the definition of neuritis and then considering acute and chronic neuritis.  I also report some relevant aspects of histopathology.

Definition of leprosy neuritis
Leprosy neuritis is an inflammatory mononeuropathy occurring in leprosy.  In can be acute or chronic.

Acute leprosy neuritis 
Acute leprosy neuritis describes the clinical state characterized by pain occurring in an obviously thickened peripheral nerve trunk such as ulnar, median, lateral popliteal nerve etc.  It may occur in cutaneous nerve trunks also, but here there is no risk of disability and deformity, although the condition may be quite distressing to the patient.  Acute neuritis is of rapid (i.e., acute) onset, over the course of a few hours to a few days.  It may have been present for a few days to a few weeks by the time the patient is seen by the physician or paramedical worker.
It may be moderately severe or severe.  In moderately severe acute leprosy neuritis patient complains of severe pain, but the movement of adjacent joint is not restricted and sleep is not disturbed because of pain.  In severe acute leprosy neuritis patient complains of severe pain and the movement of adjacent joint is restricted due to the pain and patient admits that pain disturbs sleep. 
Often, acute neuritis occurs in a background of chronic neuritis.  Acute neuritis may occur along with cutaneous manifestations of type I or type II reaction, or as an isolated clinical manifestation of the reactional process.
The term “acute leprosy neuritis" when used in the histopathological context indicates presence of foci of polymorpho nuclear leucocyte infiltration in the nerve (micro or macro “hot abscess”).
Chronic leprosy neuritis
 “Chronic leprosy neuritis” is the clinical condition where there has been long standing ‘mild’ (patient admits to having pain in the nerve only on asking about it) to ‘moderate’ nerve pain (complains of pain even without asking about it, but says it is not severe) in one or more peripheral nerve trunks of the limb(s).   
Histologically, every case of leprosy shows some evidence of chronic neuritis at some site in the peripheral nervous system.  Leprosy is not diagnosed without such evidence.   
Clinical examination
On examination, the concerned nerve trunk is obviously thickened (swollen), and very tender (very painful on palpation), such that the patient is afraid of palpation of the nerve.  Range of active movement of the adjacent joint is restricted because of pain; and/or passively increasing the range aggravates pain in the nerve.  There may be clinical nerve function deficit relating to the affected nerve trunk, which may be pre-existing or of recent origin along with the attack of acute neuritis or, pre-existing nerve function deficit may have worsened coincident with the attack of acute neuritis or, there may not be any clinically identifiable nerve function deficit.  
Indications for Steroid therapy
Onset or worsening of clinical nerve function deficit relating to the affected nerve trunk (eg., sensory loss, muscle weakness or paralysis) along with acute neuritis or even while the condition is under treatment with other drugs is an absolute indication for immediate institution of steroid therapy in adequate dosage.  Continued severe nerve pain even in the absence of increasing nerve function deficit or in a destroyed nerve trunk (with no possibility of the nerve recovering) despite adequate analgesic therapy is often relieved by steroid therapy.
Nerve conduction studies
One does not wait for or depend on nerve conduction studies for diagnosing and treating acute neuritis.  They may be used, when available, for monitoring efficacy of therapy.  Nerve conduction velocity (NCVs) may be within normal limits when only slow conducting fibres are damaged.  Marginal improvement in NCVs without clinical improvement is of no material benefit to the patient.
Early detection of leprosy neuritis
Patient is the best person to suspect early the possibility of acute neuritis and report for treatment without delay.  So the patient should be trained to look for and suspect acute neuritis as well as onset/worsening of nerve function deficit of his or her thickened nerve trunks.  The paramedical and medical personnel must be sensitized to show concern and examine the patient very carefully and sympathetically when a patient reports for suspected acute neuritis and not play down or neglect the patient.  It goes without saying that they must know how to examine such patients.

H Srinivasan, FRCS
Surgeon (Retd)
25 First Seaward Road
Chennai - 600 041
INDIA

Disability Grading Survey Results


Leprosy Mailing List – February 25th, 2012 
Ref.:    Disability Grading Survey Results
From:  C Smith, Aberdeen, Scotland, UK

Dear Salvatore,
I would be grateful if you could post the results of the Disability Grading Survey on the LML.  I have attached versions in English and Portuguese kindly translated by Duane Hinders. 
Cairns
Cairns Smith
School of Medicine and Dentistry,
University of Aberdeen,
Polwarth Building,
Foresterhill,
Aberdeen AB25 2ZD,
Scotland, UK
Telephone - (44) 1224 437266

New Leprosy Patients at ALERT, 2009/2010


Leprosy Mailing List – January 7th, 2012
Ref.:    New Leprosy Patients at ALERT, 2009/2010
From:  Shimelis N. Doni, Addis Ababa, Ethiopia

Dear Dr Noto,
Re:  New Leprosy Patients at ALERT - All Africa Leprosy and TB Education, Rehabilitation and Training Center, Addis ABABA, Ethiopia.
Method: A retrospective analysis was conducted from October 2009 to October 2010. The data were collected from the new patient registration book of the ALERT Center Leprosy Clinic.     
Objective: To analyze new patients detected at ALERT Center, Addis Ababa, Ethiopia.
Result and Discussion
Leprosy notification rate in Ethiopia remained relatively stable over the past five years, between 4000 and 5000 new patients per year according to the Ministry of Health.  A total of 429 new leprosy patients were diagnosed at ALERT (October 2009/2010); most of them, 415 (97%), were classified as Multibacillary and 9 (3%) as Paucibacillary; and 5 patients were present as pure neural leprosy.  Of the new patients 293 (68%) were males.  This male predominance reflects the difficulty of women to travel to health institutions.   A significant number of children 14 (4%) children were among the new patients, the youngest was 2 years old.  This is slightly lower than of the 7% children among new patients in Ethiopia in 2010 (Ministry of Health report).  This indicates that there is active and recent leprosy transmission in the community.  About 132 (31%) patients had a bacteriological index (BI) greater than 3.  This indicates that a significant proportion of leprosy patients are highly infectious.  Unfortunately, we do not have a contact tracing programme and depend on the patients to check his family contacts and bring in cases.
A significant proportion of patients presented with leprosy reaction, among them 175 (41%) patients were diagnosed with reversal reaction and 26 (6%) patients with an erythema nodosum leprosum (ENL) reaction at the time of first presentation.  The patients were referred from the health centers where primary health care workers have difficulties treating reactions and monitoring progress.  A significant number of patients were found to have nerve damage of which Grade 1 disability stands at 181 (42%) patients and Grade 2 at 77(18%) patients; which is much higher than the Ministry of Health leprosy report of 9% grade 2 disabilities among new patients in 2010.  Disability grade 2 is a sign of late detection (late diagnosis and treatment) which is due to fear of stigma, spending time at the holy water and lack of knowledge as well as delay in diagnosis/treatment at the health institutions.
Conclusion and Recommendation
The best cost effective strategy for leprosy prevention and control is by designing a new national leprosy training program for all health professionals for early diagnosis, treatment and   management of reactions and disability; Improve and  maintain  MDT drug delivery to all  health  institutions; thalidomide which is a treatment of choice for ENL reaction should be available to  ALERT Center which is  the only specialized dermatology center in Ethiopia; Develop a contact tracing programme; Strengthen the self-care programme; Increase community awareness and  involvement in leprosy prevention  and control; Improve the socioeconomic status of the leprosy patients.
Yours sincerely,
Dr Shimelis N Doni
Medical Director
ALERT, Addis Ababa, Ethiopia

Wednesday, June 22, 2011

Treatment of reactions sometimes needs to be extended more than 6 months

Leprosy Mailing List – May 21st, 2011
Ref:    Treatment of reactions sometimes needs to be extended more than 6 months.
From: W. J. Theuvenet, Apeldoorn, The Netherlands

Dear Dr. Naafs,
Thank you for your valuable observation (LML May 18th, 2011) that reactions often need treatment longer than 6 months.  This covers my personal experience.  In my last borderline leprosy (BL) patient the neuritis of several nerves frequently recurred in the first 24 months after putting her on MDT/ Prednisone and an increased dosage of clofazimine.  Most of the nerve(s) function responded very well on this regimen and over this period she could never really do without varying dosages of the prednisone/clofazimine, this modulating with the severity of the neuritis.  The right tibial nerve was decompressed (by the "selective meshing of the epineurium" method) at the tarsal tunnel as it did not respond within 4 months on this regimen and sensation was restored within 2 weeks after operation!  From Semmes Weinstein Monofilament (SWM) test 6.65 negative to 4.31 positive at the vulnerable Hallux andfirst metatarsophalangeal (MTP) -1 area.
Personally I feel that more research is needed as the present neuritis treatment even when applied with a longer duration, often gives some "improvement" of nerve function, but this "improvement" is hardly ever back to a functional level, be it to full restoration of nerve function.  In this situation it is sad that there is very little attention paid to the alternative of a nerve decompression.  To operate on a nerve ("nerve decompression") seems to frighten the ignorant but it is not "brain surgery" and provides often a simple alternative for the restoration of nerve function where medical treatment fails.
TENLEP may offer valuable information and any new research is welcome, as nowadays permanent nerve function loss is often too easily accepted as a consequence of leprosy.  Without this nerve function loss there would hardly be any need for stigma reduction, community based rehabilitation, empowerment etc etc.  We therefore urgently need better tools to properly treat leprosy neuritis!

With best regards,

Willem J. Theuvenet.

Leprosy situation in the Democratic Republic of Congo

Leprosy Mailing List – May 16th, 2011

Ref:    Leprosy situation in the Democratic Republic of Congo
From: J F Mukalay, Kinshasa/Gombe, Democratic Republic of Congo 

 Dear Salvatore,
I am sending this few information summarizing the leprosy situation in Congo today (please see the enclosed paper, text and slides).  It shows just the trend of new cases 2000-2009.  I couldn't get in time the 2010 data, but I expect them to be similar to 2009.
With regards,

Jean Felly Mukalay.
The Leprosy Mission Congo
124, Avenue Mongala,
Kinshasa/Gombe,
P.O. BOX 14347  KIN 1
Democratic Republic of Congo

Leprosy indicators in Gabon, 1991-2010

Leprosy Mailing List – May 4th, 2011 
Ref:     Leprosy indicators in Gabon, 1991-2010
From:  Mondjo A., Libreville, Gabon

Dear Salvatore,

Herewith are enclosed the key indicators of the leprosy programme in Gabon during the last twenty years.
Last year we reported 17 patients with WHO grade 2 disability (our population estimated = 1 800 000).  Our rate of new cases with invalidity grade 2 per 100,000 inhabitants is very high (0.93) and Gabon has planned to reduce it by 50% by the year 2015 (that is to say less than 9 cases with disability).

Best regards,

Dr Annick MONDJO

Thursday, March 3, 2011

“Leprosy reactions: the effect of gender and household contacts”

Leprosy Mailing List – February 22nd, 2011

Ref.:   “Leprosy reactions: the effect of gender and household contacts”
From: Mastrangelo G., Padua , Italy

“Leprosy reactions: the effect of gender and household contacts”
Giuseppe Mastrangelo, Joaquim da Silva Neto, Gilberto Valentim da Silva, Luca Scoizzato, Emanuela Fadda, Monique Dallapicola, Ana Luiza Folleto, Luca Cegolon
Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 106(1): 000-000, February 2011



Dear colleagues,

Please find herewith enclosed the above mentioned recent publication, that I hope could be of your interest.

Best wishes,

Giuseppe Mastrangelo

Department of Environmental Medicine and Public Health
Padua University
Padua, Italy

Infolep choice of new (e-)publications on leprosy


Leprosy Mailing List – February 17th, 2011

Ref.:   Infolep choice of new (e-)publications on leprosy
From: Erlings J., Amsterdam , Netherlands


Dear Dr Noto,

Greetings!

Below you will find a selection of new publications on leprosy.  Please contact me for full text versions.  Do you have publications on leprosy to share? Please let me know! 
With kind regards,

Jiske Erlings

INFOLEP Leprosy Information Services
P.O. Box 95005 Ι 1090 HA  Amsterdam
Netherlands

Tel.: + 31 20 5950530  Fax: +31 20 6680823
E-mail:  infolep(at)leprastichting.nl
E-mail: J.Erlings(at)Leprastichting.NL



 Journals

New issue of Leprosy Review, 2010, issue no.4
Download articles from: http://www.leprahealthinaction.org/lr/Dec10/Lep346-347.pdf



1: Di Martino Ortiz B, Masi MR, Knopfelmacher O, de Lezcano LB. [Childhood leprosy: Report of a case.]. Dermatology online journal. 2011;17(1):13.

2: Forastiero R, Martinuzzo M, De Larrañaga G, Vega-Ostertag M, Pierangeli S. Anti-?(2) glycoprotein I antibodies from leprosy patients do not show thrombogenic effects in an in vivo animal model. Journal of thrombosis and haemostasis : JTH. 2011.

3: Franco L, de Carvalho GL, Carneiro HM, Pinto SA, de Carvalho RM. [Medial canthus necrosis associated with Hansen's disease: case report.]. Arquivos brasileiros de oftalmologia. 2010;73(6):539-40.
Free full text available from:  http://www.scielo.br/pdf/abo/v73n6/v73n6a16.pdf

4: Gertler PJ, Martinez S, Premand P, Rawlings RB, Vermeersch CM. Impact evaluation in practice. Washington : World Bank; 2010.
Free full text available from:http://siteresources.worldbank.org/EXTHDOFFICE/Resources/5485726-1283444590513/IEP_001-262_final.pdf

5: Hali F, Benchikhi H, Azzouzi S, Zamiati S, Latifi A, Sbai M. [Familial histoid leprosy.]. Annales de dermatologie et de venereologie. 2011;138(1):42-5.

6: Kai M, Nguyen Phuc NH, Nguyen HA, Pham TH, Nguyen KH, Miyamoto Y, et al. 
Analysis of drug-resistant strains of mycobacterium leprae in an endemic area of Vietnam. Clin Infect Dis. 2011;52(5):e127-32.

7: Ramien ML, Wong A, Keystone JS. Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. Clin Infect Dis. 2011;52(5):e133-5.
Free full text available from: http://cid.oxfordjournals.org/content/52/5/e133.full.pdf+html

8: Sampaio LH, Stefani MM, Oliveira RM, Sousa AL, Ireton GC, Reed SG, et al. Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC infectious diseases. 2011;11(1):26.
Free full text available from: http://www.biomedcentral.com/content/pdf/1471-2334-11-26.pdf

9: Teixeira F, Ribeiro A, Bogas M, Afonso C, Araújo D. [Chronic tophaceous arthropathy and leprosy in the same patient.]. Acta reumatologica portuguesa. 2010;35(5):526-8.

10: Wiker HG, Tomazella GG, de Souza GA. 
A quantitative view on Mycobacterium leprae antigens by proteomics. Journal of proteomics. 2011.


 Thesis


Slim FJ. Functioning with leprosy impairments in The Netherlands: the consequences and diagnosis of foot abnormalities. Amsterdam: University of Amsterdam; 2011.

58th World Leprosy Day

Leprosy Mailing List – January 25th, 2011

Ref.:    58th World Leprosy Day
From:  Soutar D., London , UK



Dear Salvatore,

I would be grateful if you would post on the list the attached statement from the ILEP President, Mr René Stäheli, issued to mark the occasion of World Leprosy Day 2011.

Best regards,

Doug
Douglas Soutar
General Secretary
International Federation of Anti-Leprosy Associations
Tel: 44 (0) 207 602 69 25 – Fax:  44 (0) 207 371 16 21 – Website: www.ilep.org.uk
E-mail: doug.soutar(at)ilep.org.uk

Thursday, January 28, 2010

Can the current health delivery system in India manage the leprosy burden?

Leprosy Mailing List – November 8th, 2009

Ref.: Can the current health delivery system in India manage the leprosy burden? (see attachment)

From: Ganapati R., Mumbai, India


Dear Dr Noto,

I am enclosing my critical comments on leprosy management in some selected parts of India when I have done field studies. This was the subject of my invited lecture at the Conference of the Indian Association of Leprologists held in New Delhi on 2-4 October 2009.

Following the presentation there was a lively debate on the role of NGOs, assisting the National Leprosy Eradication Programme of the Govt. of India. Though no definite conclusions were drawn after the session which was chaired by the Chief Leprosy Program Officer of the Govt. of India, there was general agreement there is a vast scope for improvement in managing the field aspects of leprosy in India.

If you think that this write up is worth publication as an LML you may consider my request so that I may have the benefit of exchange of views from many of your readers.

Thanks & regards,

Dr R Ganapati

Director Emeritus

Bombay Leprosy Project

Monday, August 31, 2009

Enhanced Global Strategy 2011-2015

Leprosy Mailing List, August 29th, 2009

Ref.: Enhanced Global Strategy 2011-2015 (see attachment)

From: Pannikar V., New Delhi, India
--------------------------------------------------------------------------------
Dear Dr Noto,

Please find attached the final print version (English, PDF) of the Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy (2011-2015). Several hard copies of the document will be distributed to all WHO Regions, countries and partners for distribution to all health programme managers responsible for leprosy control in their area.

The purpose of these documents is to help managers of national health services to develop detailed national policies applicable to their own situation, and revise the National Manual for Leprosy Control in their respective countries.

I would like to request you to share these documents with the national programme authorities from endemic countries and other interested colleagues. In addition, I would encourage programmes to translate the document into local languages, as appropriate.

With kind regards,

V. Pannikar

Global leprosy situation, WER n. 33, 14 August 2009

Leprosy Mailing List, August 18th, 2009

Ref.: Global leprosy situation, WER n. 33, 14 August 2009 (see attachment)
From: Pannikar V., New Delhi, India

--------------------------------------------------------------------------------

Dear Dr Noto,

Please find attached the latest Weekly Epidemiological Record on the global leprosy situation. Kindly share this with colleagues in your organization and other interested people.

Many thanks for your support to the Global Leprosy Programme.

Regards,

V. Pannikar

Tuesday, July 28, 2009

Acworth Leprosy Museum, Mumbay, India

Leprosy Mailing List, July 17th, 2009
Ref.: Acworth Leprosy Museum, Mumbay, India (see attachments)
From: Mishra K. J., Mumbai, India

Dear Dr Noto,

I would like to send an article related with the initiation of the efforts to open a museum for leprosy history. I have been associated with Acworth Leprosy Hospital Research Society for one and half years and worked as a Research Assistant in regards to collection, documentation, filing and analysis of archival materials for leprosy subject for the period 1860-1953.

I request you to kindly publish it in the leprosy mailing list and pleased to inform you that "Leprosy Review" has covered this information in their "News and Item" column for this month's edition.

In addition to this, I am attaching the photograph of display of exhibit artefacts of Museum to Mr. Phatak by Dr. W.S. Bhatki, the Honourable Director of Acworth Leprosy Museum. Looking forward for your positive response.

Thanks and Regards,

Ms. Kavita J Mishra

Placement Officer
Alkesh Dinesh Mosy Institute for Financial and Management Studies
University of Mumbai
Tel.: 022-26524450/9819925109

Report of the 10th meeting of the WHO Technical Advisory Group on Leprosy Control

Leprosy Mailing List, July 17th, 2009
Ref.: Report of the 10th meeting of the WHO Technical Advisory Group on Leprosy Control (see attachment)
From: Pannikar V., New Delhi, India

Dear Dr Noto,

Please find attached the report of the 10th meeting of the WHO Technical Advisory Group on Leprosy Control held on 23 April 2009 at New Delhi, India. Kindly share this document with interested colleagues.

Regards,

V. Pannikar

WER article on drug resistance Page 264-267

Leprosy Mailing List, July 8th, 2009
Ref.: WER article on drug resistance Page 264-267
From: Pannikar V., New Delhi, India


Dear Dr Noto,


Please find attached WER (Pages 264-267) on WHO’s drug resistance surveillance in Leprosy. I believe that it is of paramount importance to keep a close watch on the drug resistance situation, particularly for the emergence of rifampicin resistant M. leprae.


WHO is planning to publish such reports at least once a year from now onwards. I will be grateful if you can share this article with your colleagues.

Regards,

V. Pannikar

Questions on leprosy research

Leprosy Mailing List,
June 17th, 2009
Ref.: Questions on leprosy research
From: Higgins S., Peterborough, England, UK

Dear Dr Noto,

I'm very interested to find out the progress we are making in research into leprosy and would be grateful if any of the members of the LML could enlighten me by answering the questions below:
What are the main current areas of research into leprosy?
What are the most recent findings in relation to leprosy and genetic predisposition, and environmental factors?
Is there any evidence for transmission of leprosy between a mother and her unborn/newborn child?
What evidence is there of leprosy occurring in young children under 3 years of age, and if it is low, is this because we lack the diagnostic tests or because this age group is relatively unaffected?
Are there any statistics to show rate of infection between family members, e.g. is it greater between spouses, siblings or parent-to-child?

Thanks and best wishes,

Siân Siân Higgins
Head of Programmes Coordination,
TLMEW Direct line: 01733 404874

WHO Press Release on the Global Programme Managers’ Meeting on Leprosy Control Strategy

Leprosy Mailing List,
June 2nd, 2009
Ref.: WHO Press Release on the Global Programme Managers’ Meeting on Leprosy Control Strategy (see attachment)
From: Pannikar V., New Delhi, India

Dear Dr Noto,

I am sending you the WHO Press Release on the recently concluded “Global Programme Managers’ Meeting on Leprosy Control Strategy” held in New Delhi, India on 20-22 April 2009.

Thank you for sharing with the discussion list.

Regards,
V. Pannikar

The educational value of our leprosy mailing list (LML)

Leprosy Mailing List,
May 28th, 2009
Ref.: The educational value of our leprosy mailing list (LML)
From: Al Aboud K., Mecca, Saudi Arabia

Dear Salvatore,

Greetings, As you know the interactive internet mailing lists, as LML, are important resources for medical professionals. Please visit this link:- http://www.skinandaging.com/content/interactive-internet-dermatology-mailing-lists-an-important-educational-tool

I would like to share with our LML colleagues this manuscript (Interactive Internet Dermatology mailing Lists: An Important Educational Tool) and I look forward for comments.

With my best wishes and regards.

Sincerely,
Dr Khalid Al Aboud
Medical Director and Consultant Dermatologist
King Faisal Hospital ,
P.O Box 5592
Makkah Saudi Arabia
Tel.: 0096625566411 ext 6666 Fax: 0096625563523
E-mail: alaboudkhalid(at)yahoo.ca

WER n. 20, 15 May 2009. Leprosy in Yemen: trends in case detection, 1982-2008

Leprosy Mailing List,
May 28th, 2009
Ref.: WER n. 20, 15 May 2009. Leprosy in Yemen: trends in case detection, 1982-2008
From: Pannikar V., New Delhi, India

Dear Dr Noto,

Please find in attachment the Weekly Epidemiological Record n. 20, 15 may 2009. It is intended for your kind information and for the members of the leprosy mailing list. Thank you very much in advance for circulating it.

I would like to encourage Countries to carefully analyze their leprosy data and look at disease trends.

Regards,
V. Pannikar

Thursday, January 1, 2009

The current leprosy situation in Brazil

Leprosy Mailing List, December 20th, 2008

 

Ref.:    The current leprosy situation in Brazil (has 4 attachments)

From:  de Pinho Andrade J. E., Rio de Janeiro, RJ, Brazil


 

 

Dear Salvatore,

 

Thanks for publishing our bulletin.  Please find the latest publication of Brazilian Ministry of Health on the current Hansen’s disease situation in the country (both Portuguese andEnglish versions).

 

The 10 major leprosy clusters comprise more than 1,100 municipalities. It would be difficult to enlist the relevant towns, districts and states involved.  I’m attaching a map ofBrazil (1, 2) – for comparison – so that one can have an idea of the spots! More information on this issue can be asked to the national leprosy program coordinator through the following e-mail: maria.leide at saude.gov.br

 

I take this occasion to wish Season’s greetings to all LML readers.

 

José Eduardo de Pinho Andrade, MD, MPH

 

Associação NLR Brasil

Avenida Marechal Câmara, 350 Sala 1002 – Centro

CEP 20.020-080 – Rio de Janeiro – RJ – Brasil

Telefones celulares: (21) 8166-8419 e (73) 8807-2122

Telefone comercial: (21) 2544-8383

Fax comercial: (21) 2532-7989

E-mail:  eduardo at hansen.org.br

Web:  www.hansen.org.br